Significant variability exists in ASB screening and treatment practices among Canadian nephrologists. These findings highlight a true evidence gap regarding management during the early posttransplant period, rather than a failure to adopt established data, and support the need for pragmatic clinical trials to guide evidence-based ASB management and antimicrobial stewardship.
Rodriguez‐Ramirez et al. (Wed,) studied this question.